Sorrento Therapeutics Inc (NASDAQ: SRNE) recently updated its recent study to its shareholders. The company announced that it recruited fit volunteers. Moreover, the study entails the investigation of STI- 9199 and is still underway. The process and patterns behind the study are almost the same as the clinical trial for STI-2099 which is also one of Sorrento’s projects.
The company announced locations where it will conduct the study
Sorrento began a safety policy following the diagnosis issued to patients and treated approximately 300 participants. During the announcement, the company declared that it should conduct the trials in three nations, including China, Mexico, and the U.S. Sorrento further anticipates discussions with the FDA regarding the study’s goal and its strategy to accomplish it.
STI-1999 induces its antibodies via nasal drops, which differs from other forms of therapies. The compound has further revealed its effectiveness during the clinical trial. Several antibodies were authorised during the COVID -19 pandemic. However, following the synthesis of the Omicron variant, the European Union decreased the amount. Currently, there is only one antibody that is availed in the E.U. market, thus administered through an injection.
Dr Mike Royal, the company’s chief medical officer, stated that they were committed to the study due to the adequate results that they had collected this far. Royal further noted that the company looks forward to the recruitment process, thus hoping that it would be swift and commendable.
The company develops treatments for cancer and autoimmune diseases
The company is on its way to becoming a front-liner in the biopharmaceutical industry. It is responsible for various treatments for malignant illnesses, including cancer and autoimmune diseases, among others. Sorrento also possesses a talented team responsible for practical products and services. The company also issues alternative therapy methods rather than utilising various and common invasive treatments.
Sorrento developed various compounds, including the resiniferatoxin compound and others. The compound is an investigational drug that the company anticipates will reduce the risk of addiction to pharmaceutical drugs such as opioids. One of the company’s leading products, ZTildo, was consented to by the FDA sometime in 2018.